Efficacy and safety of bivalirudin without post-procedure infusion in patients with coronary heart disease during elective percutaneous coronary intervention:a real-world study

作     者：Ping Wang Xin Zhao Qimin Yuan Xiaoxue Yu Lin Yang Xiaozeng Wang Ping Wang;Xin Zhao;Qimin Yuan;Xiaoxue Yu;Lin Yang;Xiaozeng Wang

作者机构：Department of CardiologyGeneral Hospital of Northern Theater CommandShenyangLiaoning 110016China Department of PharmacyThe People's Hospital of LangfangLangfangHebei 065000China Department of CardiologyThe Second Affiliated Hospital of Dalian Medical UniversityDalianLiaoning 116023China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2022年第135卷第1期

页      面：116-118页

核心收录：

学科分类：1002[医学-临床医学] 10[医学] 

主　　题：patients coronary infusion 

摘      要：To the Editor:Antithrombotic therapy is essential to prevent adverse ischemic events during and after percutaneous coronary intervention(PCI).Anticoagulation during PCI is most commonly achieved with heparin or bivalirudin.Bivalirudin does not activate platelets,does not bind to plasma proteins and has linear pharmaco-kinetics with a short half-life of 25 min.[1,2,3]These characteristics indicate that bivalirudin may be an ideal anticoagulation drug for PCI.Prior trials which were about patients with acute myocardial infarction(AMI)undergoing primary PCI showed that a bivalirudin-based anticoagulation strategy decreased the risk of major bleeding,but it was associated with an increased risk of acute stent thrombosis(ST)compared with a heparin-based strategy.[4]It was considered that short half-life of bivalirudin and delayed onset of platelet P2Y12 receptor inhibitor in AMI patients led to a blank period of antithrombotic therapy after primary PCI.